Quick Facts on Triquilar

• Aids in the prevention of pregnancy.
• Contributes to the regulation of the menstrual cycle.
• May be associated with less painful menstrual bleeding (dysmenorrhea).

---

What Triquilar Treats: Main Uses and Benefits

Triquilar is an approved medication utilized for conception control. Its primary therapeutic domain is to provide reliable contraception when used as directed. The medication contains a combination of hormones intended to assist in preventing the possibility of pregnancy.

In addition to its main use, the treatment may offer certain secondary effects related to the menstrual cycle. Clinical experience suggests that use of this medication can be associated with an improved pattern of regular menstrual bleeding. Furthermore, some individuals report a lessening of discomfort related to menstrual periods. These effects are considered complementary to the primary contraceptive action.

Who Can and Cannot Use Triquilar?

The official eligibility profile for Triquilar (Levonorgestrel and Ethinyl Estradiol) is strictly defined by regulatory authorities and focuses on absolute prohibitions related to serious health risks.

Eligibility Classification	Rule Statement (Regulatory Basis)
Populations Allowed	Females of reproductive potential for the purpose of pregnancy prevention.
Populations Contraindicated	Women over 35 years of age who smoke.
Age Restriction	Only indicated for use after menarche; use is not indicated in postmenopausal women.

Official Contraindication States: The medicine is contraindicated (must not be used) in women with a high risk of arterial or venous thrombotic diseases, including a history of deep vein thrombosis, pulmonary embolism, cerebrovascular disease, or coronary artery disease. Prohibited conditions also include current or history of breast cancer or other hormone-sensitive malignancies, severe liver disease (including liver tumours), uncontrolled hypertension, or diabetes mellitus with vascular involvement. Pregnancy is an absolute contraindication.

Eligibility Restrictions: Use is not recommended in lactating women as it may decrease milk production. The medication must be stopped at least four weeks before and through two weeks after major surgery with prolonged immobilization, due to the temporary increase in thromboembolic risk.

Triquilar Interactions with other medicines and products

This section details officially documented interaction information for Triquilar (Ethinyl Estradiol and Levonorgestrel) as defined by regulatory authorities.

---

Documented Interaction Classifications

Classification	Interacting Substance/Condition
Formal Contraindication	Hepatitis C drug regimens containing ombitasvir / paritaprevir / ritonavir, with or without dasabuvir.
Exposure-Altering (PK)	Strong or moderate CYP3A4 Inducers (e.g., certain Anticonvulsants/Antibiotics); CYP3A4 Inhibitors.
Herbal/Food	St. John's wort; Grapefruit Juice.

---

Official Interaction Statements

• Contraindicated Combinations: Co-administration with the specified Hepatitis C drug regimens is prohibited due to the risk of significant elevation of the liver enzyme Alanine Aminotransferase (ALT).
• Metabolic Effects: Certain medicinal products are known to induce hepatic/intestinal enzyme CYP3A4 metabolism, which may decrease the plasma concentrations of Triquilar's active components, leading to reduced effectiveness. Other drugs may inhibit this enzyme, resulting in significant changes to the hormone plasma levels.
• Procedural Restriction: The medication must be discontinued at least four weeks prior to and for two weeks after any elective surgery associated with an increased risk of thromboembolism or during prolonged immobilization.
• Absorption Interference: Conditions that cause changes in gastrointestinal motility, such as diarrhea or vomiting, are documented to potentially reduce the absorption of the medicine's hormones.

Central Regulation: HPO Axis Suppression and Anovulation

This medication works primarily by acting as an agonist on hormone receptors within the hypothalamus and pituitary gland. This interaction triggers a negative feedback loop that suppresses the release of the gonadotropins Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), leading to the absence of the mid-cycle LH surge and anovulation.

---

Peripheral Barrier: Cervical Mucus and Endometrial Modification

The hormones simultaneously influence peripheral tissues, specifically the cervix and endometrium. The progestin component increases the viscosity and impenetrability of the cervical mucus, establishing a highly viscous physical state that impedes sperm transport. Furthermore, the drug alters the structure of the uterine lining (endometrium), making the tissue unable to support embryonic implantation, which contributes to the multiple physiological steps involved in the drug's effect profile.

How to Use Triquilar: Administration Guidelines

Triquilar is administered as an oral contraceptive tablet used in a continuous, long-term pattern based on a structured 28-day cycle. Use involves adherence to a specific dosage and schedule, which is based on a triphasic delivery system.

---

Key Administration Principles

Administration Scope	Requirement
Route of Administration	Oral administration (swallowed)
Dosing Schedule	One tablet daily for 28 consecutive days, following the sequential order provided in the pack. The 21 active tablets contain three distinct hormone ratios.
Timing	The tablet must be taken at the same time every day to maintain consistent hormone plasma levels.
Starting Protocol	Initiation occurs on a specific day, typically the first day of menses (Day 1 Start) or the first Sunday after menses begins (Sunday Start).

---

Procedural Structure

Use of Triquilar involves a 21-day active regimen followed immediately by a 7-day hormone-free interval, maintained over successive cycles.

1. Start: Ingest the first active tablet on the designated start day.
2. Sequence: Continue to ingest one tablet orally every day, strictly following the sequential order indicated on the blister pack, covering the three color phases.
3. Cycle Completion: The next 28-day pack begins immediately after the last tablet of the preceding pack, ensuring the hormone-free interval does not exceed seven days.

There is a specific protocol for managing missed doses of active tablets, which varies based on the cycle week and may require the use of backup contraception.

Research Evidence / Overview of Studies for Triquilar

Evidence for Use in Pregnancy Prevention (Contraception)

Research exploring pregnancy prevention has relied on large-scale clinical trials and systematic reviews. These investigations included healthy females of reproductive age, measuring contraceptive efficacy, often calculated as the Pearl Index. Studies focusing on this combination reported Pearl Index measurements consistent with the prespecified criteria for contraceptive research across observed populations. However, certainty remains low regarding whether the triphasic dosing schedule offers a difference in measured contraceptive outcomes compared to modern, low-dose monophasic pills containing the same hormones.

---

Evidence Related to Menstrual Cycle Management

The medicine was studied for secondary outcomes related to systemic or functional imbalance, with research exploring measures of menstrual cycle regulation and physical discomfort. Comparative trials monitored outcomes like the incidence of unscheduled bleeding and changes in patient-reported menstrual pain scores. Research examining physical discomfort outcomes is largely drawn from broader oral contraceptive research and not isolated to this specific triphasic dose-step regimen.

---

Long-Term Follow-up and Study Durations

Pivotal trials generally monitored individuals for 12 treatment cycles (one year), with observational cohorts extending up to five years. Findings indicate that patients often remained on the regimen for the duration of the follow-up. However, long-term effects are not fully established, and the research primarily applies only to the populations studied.

---

Evidence Comparing Triphasic vs. Monophasic Regimens

A specific body of research was studied for the purpose of comparing the sequential dosing schedule against monophasic oral contraceptives. These comparisons yielded mixed findings. The body of comparative research suggests that evidence is lacking to definitively show a measurable difference in outcomes between the triphasic regimen and modern monophasic pills containing the same progestin.

---

Research Gaps and Areas of Uncertainty

A primary research gap is that comparative evidence is lacking to definitively show that the triphasic dosing schedule affects outcomes in terms of efficacy or cycle regulation. Furthermore, data for certain groups remain insufficient (e.g., adolescents or women with certain comorbidities) compared to the core measured outcomes data. Existing studies provide limited insight into the reason the triphasic approach was evaluated through its three distinct dosage steps.

Key Studies & References

1. TRIQUILAR Full Prescribing Information (Reference to Canadian Regulatory Labeling)
2. Contraceptive use: Statement on combined hormonal contraception and the risk of venous thromboembolism (WHO Technical Guidance for combined oral contraceptives, used for comparative evidence context)

Common questions about Triquilar (FAQ)

---

Q: How long does it typically take for the body to adjust to Triquilar?

Official information indicates that common side effects, such as irregular bleeding or spotting, are described as typically decreasing with time as the body adjusts to the hormones. Regulatory documents also note that the risk of serious side effects, such as blood clots, is described as highest during the first year of initial use or re-initiation.

---

Q: Does Triquilar affect the results of any common lab tests?

Yes, official patient information advises that hormonal contraceptives can affect the results of certain blood tests. Patients are generally advised to inform their healthcare providers that they are using this medication before undergoing laboratory tests.

---

Q: Does Triquilar offer protection against sexually transmitted infections (STIs)?

According to official product information, hormonal contraceptives, including Triquilar, do not offer protection against HIV/AIDS and other Sexually Transmitted Infections (STIs). Protection against STIs is not provided by hormonal contraceptives, and barrier methods, such as condoms, are generally used for this purpose.

---

Q: Can Triquilar impact fertility after stopping its use?

Studies and official information indicate that the contraceptive effects of combined oral contraceptives are reversible once the medicine is stopped. The return to normal menstrual cycles and fertility may occur within the first month, though it may take a few months for cycles to become stable again.

---

Q: Is it necessary to use a backup method of contraception when first starting Triquilar?

Instructions for starting the medication vary depending on the patient's cycle start day (Day 1 Start or Sunday Start). Official product information often outlines when contraceptive efficacy begins, and depending on the chosen start day, a backup method of birth control may be described as required for the initial period.

---

Q: How quickly does Triquilar begin to work after the first dose?

According to official patient instructions, if the pill is started on the first day of the menstrual period (Day 1 Start), the medication begins to work immediately. If starting on a later day, the full contraceptive effect is generally achieved after 7 consecutive days of taking the active pills.

---

Q: Are there differences in Triquilar's effectiveness for different body weights?

Regulatory labeling advises caution regarding the use of this medicine in patients who are overweight. While all combined oral contraceptives are highly effective when used correctly, effectiveness can vary, and consistent use is described as crucial to the medicine’s efficacy.

---

Q: What is the purpose of the inactive pills in the Triquilar pack?

The inactive tablets are hormone-free and are included to help maintain the daily habit of pill-taking throughout the full 28-day cycle. They correspond to the 7-day hormone-free interval, which is when the withdrawal bleed (period) typically occurs.

---

Q: Is it normal to have a lighter period or no period at all on Triquilar?

Regulatory guidance notes that it is common to experience a lighter bleed or even no period at all (amenorrhea) while taking hormonal contraceptives. If a period is missed, regulatory guidance often suggests consultation with a healthcare professional to rule out pregnancy or other causes.

---

Q: Is it safe to travel across time zones while taking Triquilar?

Official instructions emphasize taking the pill at the same time every day to ensure consistent hormone levels are maintained. If travel involves crossing time zones, maintaining the necessary 24-hour dosing interval may require adjustment to the time of administration to remain as consistent as possible.

---

Q: Is it possible to be allergic to any component of Triquilar?

Official information describes an allergic reaction or hypersensitivity to the active ingredients (ethinyl estradiol or levonorgestrel) or any of the other non-active components as a contraindication for the medicine's use.

---

Q: Can alcohol consumption interfere with Triquilar's effectiveness?

Official documents describe alcohol consumption as a topic that patients should generally consult a healthcare professional about while using the medication, though a direct interaction affecting contraceptive effectiveness is typically not stated.

---

Q: What is the duration of action for the hormones in Triquilar?

The hormones in the medicine are processed by the body over time. For example, the levonorgestrel component has a stated elimination half-life of 24 to 32 hours. The required consistent, daily dosing schedule ensures that the steady hormone plasma levels necessary for the contraceptive effect are maintained.

---

Q: Can Triquilar be used for conditions other than contraception?

The primary therapeutic purpose of Triquilar is pregnancy prevention (contraception). However, research evidence has also explored measures related to menstrual cycle regulation and physical discomfort as secondary outcomes, though these are not listed as official indications for use.

---

Q: Are there any common over-the-counter medications that interact with Triquilar?

Official documents list certain interactions with herbal products, such as St. John's wort, and specific foods. Beyond these, the labeling advises that patients should inform their healthcare professional and pharmacist about all prescription and non-prescription medicines being taken, as many substances can interact by changing hormone levels.

---

Q: Can Triquilar be used by women who are approaching menopause?

Triquilar is indicated for females of reproductive potential and is not indicated for use in postmenopausal women. Regulatory guidance suggests that females who are approaching menopause should consult a healthcare professional to determine if this medicine is appropriate for their current stage.

---

Q: Why is the pill pack structured with different colored tablets?

Triquilar is a triphasic pill, meaning the active tablets are designed for sequential dosing and deliver three distinct dose ratios of the hormones throughout the cycle. The different colors are included to help the user visually follow the correct sequential order to ensure the proper hormone dose is taken each day.

---

Q: Are people with a history of migraines eligible to use Triquilar?

Migraine is listed as a common side effect of the medicine. However, official labeling also lists a history of serious vascular diseases (such as stroke) as a contraindication. Given the potential link between migraines (especially those with aura) and vascular risks, evaluation by a healthcare professional is described as necessary to assess individual eligibility for use.

---

Q: Why might a healthcare provider recommend a triphasic pill like Triquilar?

The triphasic design of Triquilar is supported by pharmacological studies for its ability to deliver sequential doses of hormones. This dosing schedule was evaluated for its potential to mimic the body’s natural hormonal fluctuations more closely than some other formulations.

How to Store and Dispose of Triquilar?

Triquilar (levonorgestrel and ethinyl estradiol tablets) must be stored and handled according to official regulatory requirements to ensure product stability.

Storage Requirements

The medicine requires storage at controlled room temperature, typically between 15 C to 30 C (below 86 F). The tablets must be kept in their original container (blister pack) and protected from excessive heat, moisture, and light. To ensure child safety, it is mandatory to store the medication out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Triquilar must be discarded through regulated procedures. Official instructions state that the medicine must not be thrown away via household waste or flushed down the toilet (wastewater). Instead, return the unused product to a pharmacist or an authorized drug take-back program for proper pharmaceutical waste disposal.